List view / Grid view
In the upstream bioprocessing in-depth focus experts reveal how CRISPR is being leveraged to enhance productivity in cell line development and why industry is focusing on producing animal-component free glycosaminoglycans.
Reports suggest the market growth is driven by advances in biotechnology and its applications, as well as COVID-19 research.
A new single-use, closed-system upstream bioprocess has been developed which enables the production of large number of haematopoietic stem cells and progenitor cells.
Our full gene-to-protein workflow can support your research for rapid protein production early during drug development so you can minimize changes from R&D to bioproduction.
A group of scientists has created a novel high-throughput hit-to-lead development platform to identify engineered antibacterial lysins.
The nitric oxide treatment used during the 2003 SARS epidemic could be used as an antiviral against SARS-CoV-2, researchers say.
Pre-clinical studies in cells and hamsters have shown that potent antibodies from COVID-19 patients can prevent infection from SARS-CoV-2.
24 September 2020 | By PerkinElmer
During this on-demand webinar, two leading researchers will discuss their innovative approaches to developing novel opportunities for immunotherapy treatments.
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
Discover how you can simplify your workflow by combining microplate reading and imaging in a small footprint.
Sign up for free weekly 5-10 min videos from Horizon’s expert cell line engineers to help you improve your CRISPR editing experiments.
This webinar explains how synthetic guide RNAs are stable, eliminate cloning and sequencing steps, and avoid innate immune responses and cytotoxicity.
Regulatory T cells (Tregs) play a key role in regulating our immune system and inflammatory processes. Sangamo Therapeutics is evaluating the potential of CAR-Tregs (Tregs genetically modified with a chimeric antigen receptor, or CAR) for the development of therapies for immunological diseases, such as Crohn’s disease and multiple sclerosis, as…
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
Horizon article on the recipe for success for CRISPR editing in T cells.
